Altasciences Performs Phase I Studies for FDA Approval of Vibegron
Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials.
- Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials.
- We take tremendous pride in contributing to the FDA approval of much-needed medicines that improve the health and wellbeing of patients, said Amy Denvir, General Manager at Altasciences Kansas clinical pharmacology unit.
- Altasciences expert clinical teams provided clinical support for two drug-drug interaction studies and a bioavailability trial, conducted in 2018 and 2019, in healthy subjects.
- These trials were supported by Altasciences data services team, who performed the full data management and reporting for the associated clinical studies.